Kahn Jeremy M, Doctor Jason N, Rubenfeld Gordon D
Division of Pulmonary and Critical Care Medicine, Harborview Medical Center, 325 Ninth Avenue, Seattle, WA 98119, USA,
Intensive Care Med. 2006 Aug;32(8):1151-8. doi: 10.1007/s00134-006-0244-0. Epub 2006 Jun 21.
Stress ulcer prophylaxis with a histamine-2 receptor antagonist can reduce the risk of gastrointestinal bleeding in mechanically ventilated patients but may also increase the risk of ventilator-associated pneumonia. We sought to clarify the tradeoffs involved in selecting a prophylactic strategy.
Decision analysis.
A decision tree was constructed for a hypothetical cohort of patients receiving mechanical ventilation for an expected duration of longer than 48 h, using probabilities estimated from the published literature.
Patients in the model could receive either prophylaxis with a histamine-2 receptor antagonist or no prophylaxis. Sensitivity analyses were preformed varying the estimated probabilities over their plausible ranges.
Both strategies were associated with approximately the same baseline expected mortality (16.6% for histamine-2 receptor antagonists and 16.9% for no prophylaxis, risk difference 0.3%). Varying the estimated probabilities resulted in only small changes in both the expected mortality and the absolute risk reduction associated with the preferred treatment. At the extremes of assumptions the absolute mortality reduction ranged from 0.1% to 3.3%.
No single strategy of stress ulcer prophylaxis is preferred when mortality is used as the outcome. In the absence of a clinical trial demonstrating survival benefit the individual clinician's assumptions regarding the effect of prophylaxis on gastrointestinal bleeding and pneumonia and the attributable mortality of pneumonia vs. gastrointestinal bleeding will have a significant effect on the decision.
使用组胺-2受体拮抗剂预防应激性溃疡可降低机械通气患者发生胃肠道出血的风险,但也可能增加呼吸机相关性肺炎的风险。我们试图阐明选择预防策略时所涉及的权衡。
决策分析。
使用从已发表文献中估计的概率,为预期机械通气时间超过48小时的假设患者队列构建决策树。
模型中的患者可以接受组胺-2受体拮抗剂预防或不进行预防。进行敏感性分析,在合理范围内改变估计的概率。
两种策略的基线预期死亡率大致相同(组胺-2受体拮抗剂为16.6%,不预防为16.9%,风险差异为0.3%)。改变估计的概率只会导致预期死亡率和与首选治疗相关的绝对风险降低有小的变化。在极端假设下,绝对死亡率降低范围为0.1%至3.3%。
以死亡率作为结局时,没有单一的应激性溃疡预防策略是首选的。在缺乏证明生存获益的临床试验的情况下,个体临床医生关于预防对胃肠道出血和肺炎的影响以及肺炎与胃肠道出血的归因死亡率的假设将对决策产生重大影响。